company background image
JNJ logo

Johnson & Johnson NYSE:JNJ Stock Report

Last Price

US$152.43

Market Cap

US$368.7b

7D

-0.5%

1Y

5.5%

Updated

28 May, 2025

Data

Company Financials +

Johnson & Johnson

NYSE:JNJ Stock Report

Market Cap: US$368.7b

JNJ Stock Overview

Engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. More details

JNJ fundamental analysis
Snowflake Score
Valuation5/6
Future Growth1/6
Past Performance5/6
Financial Health5/6
Dividends5/6

Rewards

Trading at 52.8% below our estimate of its fair value

Earnings grew by 28.1% over the past year

Pays a reliable dividend of 3.41%

Trading at good value compared to peers and industry

Risk Analysis

No risks detected for JNJ from our risk checks.

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

JNJ logo
Johnson & Johnson
AN
AnalystConsensusTarget
Consensus Narrative from 23 Analysts

US 55 Billion Investment Will Drive Breakthrough Therapies

Key Takeaways Johnson & Johnson is poised for growth in immunology and oncology despite facing challenges from loss of drug exclusivity, leveraging next-gen therapies for strengthened revenue. Strategic investments in U.S. operations, acquisitions, and MedTech expansion aim to boost future earnings and efficiency, with potential restructuring in surgery to aid profitability.
View narrative
US$169.98
FV
10.3% undervalued intrinsic discount
3.70%
Revenue growth p.a.
6users have liked this narrative
0users have commented on this narrative
367users have followed this narrative
about 13 hours ago author updated this narrative
JNJ logo
Johnson & Johnson
GO
Goran_Damchevski
Equity Analyst

Rich Drug Pipeline Will Push Revenues and Earnings Higher

Key Takeaways Well-diversified drug pipeline with 52 drugs in late-stage approval - a good hedge for its patent expirations Kenvue spin off allows JNJ to focus on its more profitable Medical Devices and Pharmaceuticals segments Continued dividend increases and buybacks are affordable and will help capital returns Post Kenvue, I expect JNJ to grow revenues by 7.5% p.a. from its new baseline of $84B, and at higher margins Some risks around litigation, patent expiry and drug success are present Catalysts Robust Drug Pipeline: 52 Drugs Racing To The Finish Line In Late-Stage Approval The key threat to a pharmaceutical stock is the patent expiration of their high value assets. Should a company lack a product pipeline to bolster its future product portfolio, then losing exclusivity to any one drug can be a hit to the business.
View narrative
US$173.55
FV
12.2% undervalued intrinsic discount
6.30%
Revenue growth p.a.
16users have liked this narrative
0users have commented on this narrative
18users have followed this narrative
7 months ago author updated this narrative
JNJ logo
Johnson & Johnson
ST
StjepanK
Equity Analyst and Writer

Industry Tailwinds, Company Headwinds And New Products Will Lead To Stable Revenue Growth

Key Takeaways I expect JNJ to remain an established and mature market performer in a relatively stable sector. Some short-term company-related headwinds are cancelled out by long-term industry-related tailwinds Two main risks come from the talc-related litigation issue and patent expiration Most promising revenue growth opportunities are from cancer therapy drugs, with a TAM of $21.6b.
View narrative
US$133.00
FV
14.6% overvalued intrinsic discount
3.00%
Revenue growth p.a.
15users have liked this narrative
0users have commented on this narrative
11users have followed this narrative
11 months ago author updated this narrative
View Johnson & Johnson Community

Johnson & Johnson Competitors

Price History & Performance

Summary of share price highs, lows and changes for Johnson & Johnson
Historical stock prices
Current Share PriceUS$152.43
52 Week HighUS$169.99
52 Week LowUS$140.68
Beta0.41
1 Month Change-1.88%
3 Month Change-6.90%
1 Year Change5.53%
3 Year Change-14.23%
5 Year Change2.54%
Change since IPO24,288.84%

Recent News & Updates

Johnson & Johnson: Raising My Price Target Amid Stable EPS Growth

May 27

Johnson & Johnson's (NYSE:JNJ) Upcoming Dividend Will Be Larger Than Last Year's

May 21
Johnson & Johnson's (NYSE:JNJ) Upcoming Dividend Will Be Larger Than Last Year's

Recent updates

Johnson & Johnson: Raising My Price Target Amid Stable EPS Growth

May 27

Johnson & Johnson's (NYSE:JNJ) Upcoming Dividend Will Be Larger Than Last Year's

May 21
Johnson & Johnson's (NYSE:JNJ) Upcoming Dividend Will Be Larger Than Last Year's

Johnson & Johnson (NYSE:JNJ) Is Increasing Its Dividend To $1.30

May 02
Johnson & Johnson (NYSE:JNJ) Is Increasing Its Dividend To $1.30

Johnson & Johnson Just Proved The Bears Wrong Again

Apr 24

Johnson & Johnson (NYSE:JNJ) Is Paying Out A Larger Dividend Than Last Year

Apr 18
Johnson & Johnson (NYSE:JNJ) Is Paying Out A Larger Dividend Than Last Year

Johnson & Johnson Needs Time To Consolidate (Technical Analysis And Downgrade)

Mar 28

Kenvue + Johnson & Johnson: I Choose To Own The Whole 'Humpty Dumpty'

Mar 16

Pfizer Vs. Johnson & Johnson: Who's The Better Bargain For Investors

Mar 07

Here's Why Johnson & Johnson (NYSE:JNJ) Can Manage Its Debt Responsibly

Mar 03
Here's Why Johnson & Johnson (NYSE:JNJ) Can Manage Its Debt Responsibly

Johnson & Johnson: Rich History Of Excellence Poised To Endure

Feb 18

Why Johnson & Johnson's Strong Buy Rating Is Justified (Rating Upgrade)

Jan 30

Johnson & Johnson Dips On Q4 Earnings: Here's What The Market Isn't Seeing

Jan 22

Johnson & Johnson: Q4 Earnings May Not Prompt Sustained Directional Moves

Jan 16

Shareholder Returns

JNJUS PharmaceuticalsUS Market
7D-0.5%-0.2%0.8%
1Y5.5%-10.5%11.5%

Return vs Industry: JNJ exceeded the US Pharmaceuticals industry which returned -10.5% over the past year.

Return vs Market: JNJ underperformed the US Market which returned 11.5% over the past year.

Price Volatility

Is JNJ's price volatile compared to industry and market?
JNJ volatility
JNJ Average Weekly Movement3.6%
Pharmaceuticals Industry Average Movement11.4%
Market Average Movement8.0%
10% most volatile stocks in US Market17.2%
10% least volatile stocks in US Market4.2%

Stable Share Price: JNJ has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: JNJ's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1886138,100Joaquin Duatowww.jnj.com

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.

Johnson & Johnson Fundamentals Summary

How do Johnson & Johnson's earnings and revenue compare to its market cap?
JNJ fundamental statistics
Market capUS$368.73b
Earnings (TTM)US$21.81b
Revenue (TTM)US$89.33b
16.8x
P/E Ratio
4.1x
P/S Ratio

Is JNJ overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
JNJ income statement (TTM)
RevenueUS$89.33b
Cost of RevenueUS$27.78b
Gross ProfitUS$61.55b
Other ExpensesUS$39.74b
EarningsUS$21.81b

Last Reported Earnings

Mar 30, 2025

Next Earnings Date

Jul 16, 2025

Earnings per share (EPS)9.06
Gross Margin68.90%
Net Profit Margin24.41%
Debt/Equity Ratio66.9%

How did JNJ perform over the long term?

See historical performance and comparison

Dividends

3.4%
Current Dividend Yield
55%
Payout Ratio

Does JNJ pay a reliable dividends?

See JNJ dividend history and benchmarks
When do you need to buy JNJ by to receive an upcoming dividend?
Johnson & Johnson dividend dates
Ex Dividend DateMay 27 2025
Dividend Pay DateJun 10 2025
Days until Ex dividend2 days
Days until Dividend pay date12 days

Does JNJ pay a reliable dividends?

See JNJ dividend history and benchmarks

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/28 10:18
End of Day Share Price 2025/05/28 00:00
Earnings2025/03/30
Annual Earnings2024/12/29

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Johnson & Johnson is covered by 60 analysts. 22 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David ToungArgus Research Company
Charles ButlerBarclays
Matthew MiksicBarclays